Table 4. Post-CL56 hormone characteristics and subsequent response in 17 patients.

Post-CL56 treatment
Patient no.	Castrate	GnRH analogue	MAB	% PSA declinea	Duration (months)	Stilb/steroid	% PSA declinea	Duration (months)	Time from CL56 to postchemotherapy hormone treatment (months)
1	Yes	Yes	Yes	PD		No	—	—	3.6
2b	Yes	No	Yes	PD		Yes	90%	11	19.0
3	Yes	Yes	Yes	PD		No	—	—	3.2
4	Yes	Yes	No	10%	2.5	Yes	20%	4	8.0
5	Yes	Yes	No	PD	—	Yes	PD	—	5.5
6	Unknown	No	No	—	—	Yes	45%	4	4.6
7	Unknown	Yes	Yes	PD	—	Yes	PD	—	4.0
8b	Yes	No	Yes	PD	—	—	—	—	8.2
9	No	Yes	No	55%	6	Yes	PD	—	9.1
10	Unknown	Yes	Yes	97%	6.0+	No	—	—	16.1
11	Unknown	Yes	No	45%	2	No	—	—	3.8
12	Yes	Yes	No	7%	3	No	—	—	7.2
13	Yes	Yes	No	PD	—	—	—	—	2.5
14	Yes	Yes	No	PD	—	—	—	—	3.8
15	Unknown	Yes	Yes	30%	3	Yes	PD	—
16	Yes	No	Yes	PD	—	—	—	—	3.7
17	No	Yes	No	PD	—	Yes	15%	2	3.8

MAB=maximum androgen blockade.

Stilb/steroid=diethylstilbestrol and steroid.

^aFrom the start of hormone therapy.

^bPatient had orchidectomy.